Pfizer PFE D&A
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Pfizer's D&A?
- Pfizer (PFE) reported D&A of $1.61B in Q1 2026.
- How has Pfizer's D&A changed year-over-year?
- Pfizer's D&A increased by 33.2% year-over-year, from $1.21B to $1.61B.
- What is the long-term trend for Pfizer's D&A?
- Over 4 years (2021 to 2025), Pfizer's D&A has grown at a 6.0% compound annual growth rate (CAGR), from $3.86B to $4.88B.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.